Literature DB >> 17400419

Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma.

C Möbius1, C Demuth, T Aigner, M Wiedmann, C Wittekind, J Mössner, J Hauss, H Witzigmann.   

Abstract

OBJECTIVES: Angiogenesis is essential for tumor growth and metastasis. An association between microvessel density, a measure of tumor angiogenesis, and conventional prognostic variables has been shown for many different tumor entities. In extrahepatic cholangiocarcinoma, the VEGF expression and microvessel density have rarely been investigated.
METHODS: Paraffin-embedded specimens from 51 resected adenocarcinomas of the extrahepatic bile duct were immunostained for vascular endothelial growth factor A (VEGF A) and CD 34 to evaluate the microvessel density (MVD). VEGF A staining was evaluated by combining intensity and percentage of positive tumor cells, as low (expression equal or below the median), or high (above the median). Microvessel density was assessed using a method published by Weidner et al.
RESULTS: Median disease free survival (DFS) of the study group was 12.5 months (range, 1-66.3 months). DFS was calculated in the 39 patients with complete resection. It was significantly better in patients with low microvessel density than DFS in patients with high microvessel density (33 months (range, 3-66.3 months) vs. 21.8 months (range, 1.6-31.6 months); p=0.022). In contrast, VEGF A expression did not correlate with survival. There was a trend toward a higher VEGF A expression in highly vascularized tumors (p=0.08), but failed to reach statistic significance.
CONCLUSIONS: The present study indicates, that vascularisation has an important impact on survival of extrahepatic cholangiocarcinoma patients. Other molecules than VEGF A are probably involved in neovascularization in extrahepatic cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400419     DOI: 10.1016/j.ejso.2007.02.020

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  31 in total

1.  Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Authors:  Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

Authors:  Chantal Dreyer; Marie-Paule Sablin; Mohamed Bouattour; Cindy Neuzillet; Maxime Ronot; Safi Dokmak; Jacques Belghiti; Nathalie Guedj; Valérie Paradis; Eric Raymond; Sandrine Faivre
Journal:  World J Hepatol       Date:  2015-04-28

Review 3.  Recent advances in the regulation of cholangiocarcinoma growth.

Authors:  Heather Francis; Gianfranco Alpini; Sharon DeMorrow
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

4.  Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes.

Authors:  Paolo Onori; Eugenio Gaudio; Antonio Franchitto; Gianfranco Alpini; Heather Francis
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 5.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

6.  Clinical implications of PTEN and VEGF expression status, as well as microvessel density in esophageal squamous cell carcinoma.

Authors:  Wei Qu; Jin-Dong Fu; Fang Yang; Gong-Li Yang; Ya-Li Zhang; Xin-Ying Wang; Hong-Xiang Gu; Hai-Yan Zhang; Ling Wang
Journal:  Oncol Lett       Date:  2015-06-29       Impact factor: 2.967

7.  Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma.

Authors:  Yuxia Han; Wenxia Zhang; Yanfeng Liu
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

8.  TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma.

Authors:  Shanglei Ning; Sen Guo; Jianjun Xie; Yunfei Xu; Xiaofei Lu; Yuxin Chen
Journal:  J Gastrointest Surg       Date:  2012-12-01       Impact factor: 3.452

9.  Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment.

Authors:  Dinorah Leyva-Illades; Matthew McMillin; Matthew Quinn; Sharon Demorrow
Journal:  Transl Gastrointest Cancer       Date:  2012

10.  Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature.

Authors:  Ling Geng; Girish Rachakonda; D James Morré; Dorothy M Morré; Peter A Crooks; Vijayakumar N Sonar; Joseph L Roti Roti; Buck E Rogers; Suellen Greco; Fei Ye; Kenneth J Salleng; Soumya Sasi; Michael L Freeman; Konjeti R Sekhar
Journal:  FASEB J       Date:  2009-04-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.